SOAT1 and neoplasm: Because treatment decisions are informed by clinical and pathological characteristics, including tumor aggressiveness, disease stage, molecular features, and patient performance status, it is possible that these baseline factors contribute to the distribution of JAK-STAT alterations across treatment groups.